We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Clovis Oncology Inc (PK) | USOTC:CLVSQ | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.015 | 0.00 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Title of each class |
Trading symbol(s)(1) |
Name of each exchange on which registered | ||
(1) | On December 21, 2022, our common stock was suspended from trading on the NASDAQ Global Select Market (“NASDAQ”). On December 21, 2022, our common stock began trading on the OTC Pink Marketplace maintained by the OTC Markets Group, Inc. under the symbol “CLVSQ.” On December 29, 2022, NASDAQ filed a Form 25 delisting our common stock from trading on NASDAQ, which delisting became effective at the opening of the trading session on January 9, 2023. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item 3.03 | Material Modifications to the Rights of Security Holders. |
As previously disclosed, on December 11, 2022, Clovis Oncology, Inc. (the “Company”) and certain of its subsidiaries (such subsidiaries being Clovis Oncology Ireland Limited (“Clovis Ireland”) and Clovis Oncology UK Limited (“Clovis UK”, and together with the Company and Clovis Ireland, the “Debtors”)) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”).
On June 16, 2023, the Court entered an order (the “Confirmation Order”) confirming the Third Amended Joint Chapter 11 Plan of Liquidation for Clovis Oncology, Inc. and Its Affiliated Debtors, dated June 13, 2023 (as amended, modified, or supplemented from time to time, the “Plan”). The Company expects the Plan to become effective on or about July 7, 2023.
Under the Plan, all outstanding shares of common stock of the Company (including shares of common stock issuable under equity awards granted under the Company’s equity incentive plans) will be canceled and discharged and holders of such equity interests will not receive or retain any property on account thereof at this time. In the event that there is in excess of $250,000 of value remaining in the Debtors’ estates following payment in full of all creditors and claim holders of the Debtors (including all secured and unsecured creditors), the Liquidation Trustee, the trustee designated by the Plan to oversee the wind-down and liquidation of the Debtors and their subsidiaries and their remaining estates, may, in the Liquidation Trustee’s reasonable judgment, issue nontransferable contingent value rights to holders of common stock of the Company as of April 18, 2023, entitling such holders to the right to receive contingent distributions from the assets of the Liquidation Trust, if any. The Company does not currently anticipate that all senior creditors will be paid in full, and therefore does not expect that equityholders of the Company will receive any distribution under the Plan.
The Company’s securityholders are cautioned that trading in the Company’s securities is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Cases.
Item 7.01 | Regulation FD Disclosure. |
On June 30, 2023, the Company, Clovis UK and Clovis Ireland each filed their monthly operating reports (collectively, the “Monthly Operating Reports”), with the Court for the reporting month ended May 31, 2023, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference.
The Company expects to file future Monthly Operating Reports and other documents with the Court while the Cases remain pending. The filing of such reports and other documents may not be accompanied by a Form 8-K filing. The reports and other documents will also be available for review free of charge at https://cases.ra.kroll.com/Clovis/. Investors should review this website for additional information regarding the Company and the Cases.
- 2 -
Cautionary Note Regarding the Monthly Operating Reports
The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Monthly Operating Reports, which were not prepared for the purpose of providing the basis for an investment decision relating to the Company’s securities. The Monthly Operating Reports are limited in scope and have been prepared solely for the purpose of complying with requirements of the Court. The Monthly Operating Reports were not reviewed by independent accountants, are in a format prescribed by applicable bankruptcy laws, and are subject to future adjustment. The financial information in the Monthly Operating Reports are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and, therefore, may exclude items required by GAAP, such as certain reclassifications, eliminations, accruals, valuations and disclosures. The Monthly Operating Reports also relate to periods that are different from the historical periods required in the Company’s reports pursuant to the Securities Act of 1933, as amended, or the Exchange Act.
Limitation on Incorporation by Reference
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 is being furnished for informational purposes only and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. The filing of this current report (including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 attached hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD.
Cautionary Note Regarding Forward-Looking Statements
This Form 8-K includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that forward-looking statements are not guarantees of future performance and that our actual financial condition and liquidity may differ materially from the forward-looking statements contained herein. Any forward-looking statements that we make in this Form 8-K speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 8-K or to reflect the occurrence of unanticipated events. The Company’s forward-looking statements in this Form 8-K include, but are not limited to, statements about payments to creditors and recoveries by equityholders. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
- 3 -
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits:
Exhibit | Description | |
99.1 | Clovis Oncology, Inc., Monthly Operating Report, dated May 31, 2023. | |
99.2 | Clovis Oncology Ireland Limited, Monthly Operating Report, dated May 31, 2023. | |
99.3 | Clovis Oncology UK Limited, Monthly Operating Report, dated May 31, 2023. | |
104 | The cover page from Clovis Oncology, Inc.’s Current Report on Form 8-K is formatted in iXBRL. |
- 4 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 30, 2023 | ||||||
CLOVIS ONCOLOGY, INC. | ||||||
By: | /s/ Paul Gross | |||||
Name: | Paul Gross | |||||
Title: | Executive Vice President and General Counsel |
- 5 -
Exhibit 99.1
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 12/11/2022 Months Pending: Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtors Full-Time Employees (current): 45 Debtors Full-Time Employees (as of date of order for relief): 120 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Andrew Mordkoff Andrew S. Mordkoff Signature of Responsible Party Printed Name of Responsible Party 06/29/2023 Date 787 Seventh Avenue, New York, New York 10019-6099 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies. UST Form 11-MOR (12/01/2021) 1
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $85,928,683 b. Total receipts (net of transfers between accounts) $116,515,311 $248,227,293 c. Total disbursements (net of transfers between accounts) $76,542,778 $129,408,652 d. Cash balance end of month (a+b-c) $125,901,216 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $76,542,778 $129,408,652 Part 2: Asset and Liability Status Current Month (Not generally applicable to Individual Debtors. See Instructions.) a. Accounts receivable (total net of allowance) $1,715,811 b. Accounts receivable over 90 days outstanding (net of allowance) $434,424 c. Inventory ( Book Market Other (attach explanation)) $0 d Total current assets $166,073,884 e. Total assets $234,088,339 f. Postpetition payables (excluding taxes) $39,160,451 g. Postpetition payables past due (excluding taxes) $4,555,419 h. Postpetition taxes payable $0 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $39,160,451 k. Prepetition secured debt $346,993,967 l. Prepetition priority debt $0 m. Prepetition unsecured debt $475,901,976 n. Total liabilities (debt) (j+k+l+m) $862,056,394 o. Ending equity/net worth (e-n) $-627,968,055 Part 3: Assets Sold or Transferred Current Month Cumulative a. Total cash sales price for assets sold/transferred outside the ordinary course of business $0 $0 b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 Part 4: Income Statement (Statement of Operations) Current Month Cumulative (Not generally applicable to Individual Debtors. See Instructions.) a. Gross income/sales (net of returns and allowances) $-51,583,319 b. Cost of goods sold (inclusive of depreciation, if applicable) $-25,350 c. Gross profit (a-b) $-51,557,969 d. Selling expenses $228,165 e. General and administrative expenses $4,321,718 f. Other expenses $-903,774 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $207,080 i. Taxes (local, state, and federal) $28,649 j. Reorganization items $8,921,368 k. Profit (loss) $-63,947,015 $-190,845,170 UST Form 11-MOR (12/01/2021) 2
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 Part 5: Professional Fees and Expenses Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative a. Debtors professional fees & expenses (bankruptcy) Aggregate Total $4,822,031 $14,925,995 $4,822,031 $14,925,995 Itemized Breakdown by Firm Firm Name Role i Kroll Restructuring Administrat Other $0 $841,823 $0 $841,823 ii AlixPartners, LLP Financial Professional $613,704 $2,456,722 $613,704 $2,456,722 iii Willkie Farr & Gallagher LLP Lead Counsel $1,764,481 $5,891,543 $1,764,481 $5,891,543 iv Morris, Nichols, Arsht & Tunne Local Counsel $190,630 $727,365 $190,630 $727,365 v Perella Weinberg Partners Other $1,182,035 $1,842,413 $1,182,035 $1,842,413 vi Ducera Partners LLC Other $150,000 $300,133 $150,000 $300,133 vii Morris Foerster Other $586,423 $1,634,629 $586,423 $1,634,629 viii Potter Anderson Other $223,265 $431,343 $223,265 $431,343 ix Alvarez & Marsal Other $0 $466,240 $0 $466,240 x Jefferies Other $111,494 $333,784 $111,494 $333,784 xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi UST Form 11-MOR (12/01/2021) 3
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii UST Form 11-MOR (12/01/2021) 4
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative b. Debtors professional fees & expenses (nonbankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv UST Form 11-MOR (12/01/2021) 5
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi UST Form 11-MOR (12/01/2021) 6
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii UST Form 11-MOR (12/01/2021) 7
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 xcix c c. All professional fees and expenses (debtor & committees) $4,822,031 $14,925,995 $4,822,031 $14,925,995 Part 6: Postpetition Taxes Current Month Cumulative a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $0 $0 d. Postpetition employer payroll taxes paid $0 $0 e. Postpetition property taxes paid $0 $0 f. Postpetition other taxes accrued (local, state, and federal) $0 $0 g. Postpetition other taxes paid (local, state, and federal) $0 $0 Part 7: QuestionnaireDuring this reporting period: a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Workers compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930? UST Form 11-MOR (12/01/2021) 8
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 Part 8: Individual Chapter 11 Debtors (Only) a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtors progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustees or examiners duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustees systems of records notice, UST-001, Bankruptcy Case Files and Associated Records. See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Daniel W. Muehl Daniel W. Muehl Signature of Responsible Party Printed Name of Responsible Party Executive Vice President and Chief Financial Officer 06/29/2023 Title Date UST Form 11-MOR (12/01/2021) 9
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 PageOnePartOne PageOnePartTwo PageTwoPartOne PageTwoPartTwo UST Form 11-MOR (12/01/2021) 10
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 Bankruptcy1to50 Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100 UST Form 11-MOR (12/01/2021) 11
Debtors Name Clovis Oncology, Inc. Case No. 22-11292 PageThree PageFour UST Form 11-MOR (12/01/2021) 12
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Cash Receipts and Disbursements Reporting Period: May 01May 31, 2023 Debtor Third-Party Cash Disbursements Clovis Oncology, Inc. 1 $ 76,542,778 Clovis Oncology UK Limited $ 5,349,082 Clovis Oncology Ireland Limited $ 134,085 Total $ 82,025,945 Debtor Third-Party Cash Receipts Clovis Oncology, Inc. 2 $ 118,386,058 Clovis Oncology UK Limited $ 3,402,175 Clovis Oncology Ireland Limited $ Total $ 121,788,233 (1) Includes $39.7M in DIP repayment (2) Includes $102.3M and $8.5M in proceeds related to the sale of Rubraca and FAP respectively #AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Bank Account Information Reporting Period: May 01May 31, 2023 Debtor Bank Last 4 Digits Description Balance as of Month End (USD) Clovis Oncology, Inc. JP Morgan 9101 Lockbox Account 8,328,224 Clovis Oncology, Inc. JP Morgan 8623 Operating Account 28,880,863 Clovis Oncology, Inc. JP Morgan 9601 Operating Account 80 Clovis Oncology, Inc. JP Morgan 9602 Operating Account 2,056 Clovis Oncology, Inc. JP Morgan 3424 Operating Account 446 Clovis Oncology, Inc. JP Morgan 8157 Investment Account 69,022,573 Clovis Oncology, Inc. JP Morgan 2038 Investment Account 100,000 Clovis Oncology, Inc. JP Morgan 1915 Professional Fees Account 18,056,174 Clovis Oncology, Inc. JP Morgan 7602 Utilitiy Deposits Account 10,800 Clovis Oncology, Inc. JP Morgan 7669 FAP Proceeds Account 1,500,000 Clovis Oncology UK Limited JP Morgan 4225 Lockbox Account 420,983 Clovis Oncology UK Limited JP Morgan 2330 Operating Account 6,211,218 Clovis Oncology Ireland Limited JP Morgan 0565 Lockbox Account 2,207,853 Clovis Oncology Ireland Limited JP Morgan 1185 Operating Account 225,735 Sub TotalBank Accounts 134,967,004 Total 134,967,004 #AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Balance Sheet as of May 31, 2023 Reporting Period: May 01May 31, 2023 Clovis Oncology UK Clovis Oncology Ireland Clovis Oncology, Inc. USD Actuals Limited Limited Assets Current Assets: Cash and Cash Equivalents 125,901,215 6,632,201 2,433,588 Trade Accounts Receivable, Net 1,715,811 1,574,298Interco Receivables 23,824,280 350 21,431,258 Pre-PetitionInter Company Debtor Receivables Inventories Prepayments and Deposits 14,406,182 126,030 3,408 Other AssetsCurrent 226,394 2,316,152 880,183 IC Investment in Subsidiaries 2 229,143 Total Current Assets 166,073,884 10,878,173 24,748,437 Non-Current Assets: Property, Plant and Equipment, Net 127,026 108,828Goodwill 63,074,218 Other Intangible Assets, Net Other AssetsNon-current 4,813,211 135,705 25,949 Total Non-Current Assets 68,014,455 244,533 25,949 Total Assets 234,088,339 11,122,706 24,774,386 Liabilities Current Liabilities: DIP Financing 5,276,243 Trade Accounts Payable, Net 4,798,437 13,551 10,925 Interco Payables 7,914,715 5,833,625 18,291,125 Misc. Liabilities & Accrued Expenses 21,137,559 2,635,098 184,128 Accrued Taxes (Income, Payroll, etc.) (16,203) 1,110,406 272,309 Lease LiabilityShort-term 49,700 113,932 17,497 Other Notes PayableCurrent Total Current Liabilities 39,160,451 9,706,613 18,775,983 Non-Current Liabilities Lease LiabilityLong-term 6,748 Total Non-Current Liabilities 6,748 Liabilities Subject to Compromise 822,895,943 778,509 21,778 Total Liabilities 862,056,394 10,485,122 18,804,510 Equity Common Stock 145,470 2 141 Additional Paid in Capital 2,691,516,957 Accumulated Other Comprehensive Loss (41,905,090) (461,115) 27,615 Accumulated Deficit (3,277,725,392) 1,098,698 5,942,121 Total Equity (627,968,055) 637,584 5,969,877 Total Liabilities and Equity 234,088,339 11,122,706 24,774,386 Notes: 1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change. #AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Statement of Operations for the month of May 2023 Reporting Period: May 01May 31, 2023 Clovis Oncology UK Clovis Oncology Ireland Clovis Oncology, Inc. USD Actuals Limited Limited Total Revenue (432,544) 44,401 8,474,789 Operating Expenses: Cost of Goods Sold 7,3108,501,577 Royalty Expense (32,660) Research and Development (1,238,997) General and Administrative 4,321,718 431,103 52,148 Selling Expenses 228,165 13,808Operating Taxes 28,649 Other Operating Expenses Total Operating Expenses 3,314,185 444,911 8,553,725 Total Operating Profit (Loss) (3,746,729) (400,510) (78,936) Other Income and Expenses: Interest Income 207,080 Gain/(Loss) from Asset Sales, Net (51,150,775) Interest Expense Foreign Currency Translation Adjustments 335,223 (132,819) 253,761 Gain/(Loss) on Available-For-Sale Securities Reorganization Costs 8,921,368 Income Tax Expense Net Other Income/(Loss) (60,200,286) 132,819 (253,761) Net Income (63,947,015) (267,691) (332,697) Notes: 1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future. #AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Accounts Receivable Reconciliation and Aging Reporting Period: May 01May 31, 2023 Clovis Oncology, Inc. Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 1,438,175 442,935 1,881,110 Less: Prompt Pay Discounts & Returns (156,788) (8,511) (165,299) Less: Allowance for Bad Debts Net Accounts Receivable 1,281,387 434,424 1,715,811 Clovis Oncology UK Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 1,574,298 1,574,298 Less: Allowance for Bad Debts Net Accounts Receivable 1,574,298 1,574,298 Clovis Oncology Ireland Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable Less: Allowance for Bad Debts Net Accounts Receivable #AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Post-Petition Accounts Payable Aging Reporting Period: May 01May 31, 2023 Debtor Total Current 0-30 Days 31-60 Days 61-90 Days 91+ Days Clovis Oncology, Inc. 4,798,437 243,018 2,042,372 825,368 1,234,824 452,855 Clovis Oncology UK Limited 13,551 13,551 Clovis Oncology Ireland Limited 10,925 9,378 1,547 Net Accounts Payable 4,822,914 265,947 2,042,372 825,368 1,234,824 454,402 Notes: 1) While the Debtors AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case. #AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Capital Assets Reporting Period: May 01May 31, 2023 Clovis Oncology UK Clovis Oncology Ireland Clovis Oncology, Inc. USD Actuals Limited Limited Net Book Value Computer Equipment 115,396 103,138Furniture and Fixtures (0) 4,919Lab Equpment 0 Leasehold Improvements 0 (0)Licensed Software Manufacturing Equipment 4,685 Office Equipment (0) 771Trade Booth Net Book Value 120,081 108,828 #AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Payments to Insiders Reporting Period: May 01May 31, 2023 Clovis Oncology UK Clovis Oncology Ireland Clovis Oncology, Inc. USD Actuals Limited Limited Payments to Insiders 1,130,345 The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of May 1 through May 31, 2023. With respect to insiders, all cash payments made were on account of ordinary course salaries, court approved incentive or retention payments, and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period. /s/ Daniel W. Muehl 6/29/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual Notes: 1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors Statements of Financial Affairs. The amount listed Includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits, and expense reimbursements. #AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Status of Post-Petition Taxes Reporting Period: May 01May 31, 2023 The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute. /s/ Daniel W. Muehl 6/29/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual #AlixPartners General
Exhibit 99.2
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case No. 22-11294 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating
Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 12/11/2022 Months Pending: Reporting Method: Industry Classification: Accrual Basis Cash Basis Debtors
Full-Time Employees (current): 0 Debtors Full-Time Employees (as of date of order for relief): 1 Supporting Documentation (check all that are attached): (For jointly administered debtors, any
required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and
equity (net worth) or deficit Statement of operations (profit or loss statement)
Accounts receivable aging Postpetition liabilities aging Statement of capital
assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Andrew
Mordkoff Andrew S. Mordkoff Signature of Responsible Party Printed Name of Responsible Party 06/29/2023 Date 787 Seventh Avenue, New York, New York 10019-6099 Address
STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies. UST Form 11-MOR (12/01/2021) 1
Debtors Name Clovis Oncology Ireland Limited Case No. 22-1129 Part 1: Cash Receipts
and Disbursements Current MonthCumulative a. Cash balance beginning of month $2,680,032 b. Total receipts (net of transfers between accounts)
$-112,358$2,523,072 c. Total disbursements (net of transfers between accounts) $134,085$1,230,871 d. Cash balance end of month
(a+b-c) e. Disbursements made by third party for the benefit of the estate $0 f. Total disbursements for quarterly fee calculation (c+e) $1,230,871 Part 2: Asset
and Liability Status (Not generally applicable to Individual Debtors. See Instructions.) Current Month a. Accounts receivable (total net of allowance) $0 b. Accounts receivable
over 90 days outstanding (net of allowance) $0 c. Inventory ( BookMarket Other (attach explanation))$0 d Total current assets $24,748,437
e. Total assets $24,774,386 f. Postpetition payables (excluding taxes) $18,510,422 g. Postpetition payables
past due (excluding taxes) $1,547 h. Postpetition taxes payable $272,309 i. Postpetition taxes past due $0
j. Total postpetition debt (f+h) $18,782,731 k. Prepetition secured debt $0 l. Prepetition
priority debt $0 m. Prepetition unsecured debt $21,778 n. Total liabilities (debt) (j+k+l+m) $18,804,509 o. Ending equity/net worth (e-n)
$5,969,877 Part 3: Assets Sold or Transferred Current MonthCumulative Total cash sales price for assets sold/transferred outside the ordinary course of business
$0 $0 Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business
$0 $0 Net cash proceeds from assets sold/transferred outside the ordinary course of business
(a-b) $0 $0 a. b. c. Part 4: Income Statement (Statement of Operations) Current Month Cumulative (Not generally applicable to Individual Debtors. See
Instructions.) a. Gross income/sales (net of returns and allowances) $8,474,789 b. Cost of goods sold (inclusive of depreciation, if applicable) $8,501,577
c. Gross profit (a-b) $-26,788 d. Selling expenses $0 e. General and administrative expenses $52,148
f. Other expenses $253,761 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $0 i. Taxes (local, state, and federal) $0
j. Reorganization items $0 k. Profit (loss) $-332,697 $4,398,617 UST Form 11-MOR (12/01/2021) 2
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
a. Approved Current MonthApproved CumulativePaid Current MonthPaid Cumulative
Debtors professional fees & expenses (bankruptcy) Aggregate Total
Itemized | Breakdown by Firm |
Firm Name Role
i
ii
iii
iv
v
vi
vii
viii
ix
x
xi
xii
xiii
xiv
xv
xvi
xvii
xviii
xix
xx
xxi
xxii
xxiii
xxiv
xxv
xxvi
xxvii
xxviii
xxix
xxx
xxxi
xxxii
xxxiii
xxxiv
xxxv
xxxvi
UST Form 11-MOR
(12/01/2021) 3
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
xxxvii
xxxvii
xxxix
xl
xli
xlii
xliii
xliv
xlv
xlvi
xlvii
xlviii
xlix
l
li
lii
liii
liv
lv
lvi
lvii
lviii
lix
lx
lxi
lxii
lxiii
lxiv
lxv
lxvi
lxvii
lxviii
lxix
lxx
lxxi
lxxii
lxxiii
lxxiv
lxxv
lxxvi
lxxvii
lxxvii
UST Form 11-MOR (12/01/2021) 4
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
lxxix
lxxx
lxxxi
lxxxii
lxxxii
lxxxiv
lxxxv
lxxxvi
lxxxvi
lxxxvi
lxxxix
xc
xci
xcii
xciii
xciv
xcv
xcvi
xcvii
xcviii
xcix
c
ci
b. Approved Current MonthApproved
CumulativePaid Current MonthPaid Cumulative
Debtors professional fees & expenses (nonbankruptcy) Aggregate Total
Itemized | Breakdown by Firm |
Firm Name Role
i
ii
iii
iv
v
vi
vii
viii
ix
x
xi
xii
xiii
xiv
UST Form 11-MOR
(12/01/2021) 5
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
xv
xvi
xvii
xviii
xix
xx
xxi
xxii
xxiii
xxiv
xxv
xxvi
xxvii
xxviii
xxix
xxx
xxxi
xxxii
xxxiii
xxxiv
xxxv
xxxvi
xxxvii
xxxvii
xxxix
xl
xli
xlii
xliii
xliv
xlv
xlvi
xlvii
xlviii
xlix
l
li
lii
liii
liv
lv
lvi
UST Form 11-MOR (12/01/2021) 6
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
lvii
lviii
lix
lx
lxi
lxii
lxiii
lxiv
lxv
lxvi
lxvii
lxviii
lxix
lxx
lxxi
lxxii
lxxiii
lxxiv
lxxv
lxxvi
lxxvii
lxxvii
lxxix
lxxx
lxxxi
lxxxii
lxxxii
lxxxiv
lxxxv
lxxxvi
lxxxvi
lxxxvi
lxxxix
xc
xci
xcii
xciii
xciv
xcv
xcvi
xcvii
xcviii
UST Form 11-MOR (12/01/2021) 7
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
xcix
c
c. All professional fees and expenses (debtor & committees) $0$0$0$0
Part 6: Postpetition Taxes Current Month Cumulative
a. Postpetition income taxes accrued (local, state, and federal) $0$0
b. Postpetition income taxes paid (local, state, and federal) $0$0
c. Postpetition employer payroll taxes accrued $0$0
d. Postpetition employer payroll taxes paid $0$0
e. Postpetition property taxes paid $0$0
f. Postpetition other taxes accrued (local, state, and federal) $0$0
g. Postpetition other taxes paid (local, state, and federal) $0$0
a. Were any payments made on prepetition debt? (if yes, see Instructions) YesNo
b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions)
c. Were any payments made to or on behalf of insiders?
d. Are you current on postpetition tax return filings?
e. Are you current on postpetition estimated tax payments?
Yes No
Yes No
Yes No
Yes No
f. Were all trust fund taxes remitted on a current basis? YesNo
g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions)
h. Were all payments made to or on behalf of professionals approved by the court?
Yes No
Yes No N/A
i. Do you have: Workers compensation insurance?YesNo
If yes, are
your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance?YesNo
If yes, are your premiums current? Yes No N/A (if no, see Instructions)
General liability insurance? Yes No
If yes, are your premiums
current? Yes No N/A (if no, see Instructions)
j. Has a plan of
reorganization been filed with the court? YesNo
k. Has a disclosure statement been filed with the court? YesNo
l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?
Yes No
UST Form 11-MOR
(12/01/2021) 8
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
Part 8: Individual Chapter 11 Debtors (Only)
a. Gross income (receipts) from salary and wages $0
b. Gross income (receipts) from self-employment $0
c. Gross income from all other sources $0
d. Total income in the reporting period (a+b+c) $0
e. Payroll deductions $0
f. Self-employment related expenses $0
g. Living expenses $0
h. All
other expenses $0
i. Total expenses in the reporting period (e+f+g+h) $0
j. Difference between total income and total expenses (d-i) $0
k. List the total amount of all postpetition debts that are past due $0
l. Are you required to pay any Domestic Support Obligations as defined by 11
U.S.C § 101(14A)? Yes No
m. If yes, have
you made all Domestic Support Obligation payments? Yes NoN/A
Privacy Act Statement
28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C.
§§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28
U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtors progress through the bankruptcy system, including the
likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustees or
examiners duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes.
For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustees systems of records notice, UST-001, Bankruptcy Case Files and
Associated Records. See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in
the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).
I declare under penalty of
perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.
/s/ Daniel W. Muehl
Signature of Responsible Party
Executive Vice President and Chief Financial Officer
Title
Daniel W. Muehl
Printed Name of Responsible Party
06/29/2023
Date
UST Form 11-MOR (12/01/2021) 9
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
PageOnePartOne
PageOnePartTwo
PageTwoPartOne
PageTwoPartTwo
UST Form 11-MOR (12/01/2021) 10
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
Bankruptcy1to50
Bankruptcy51to100
NonBankruptcy1to50
NonBankruptcy51to100
UST Form 11-MOR (12/01/2021) 11
Debtors Name Clovis Oncology Ireland Limited Case No. 22-11294
PageThree
PageFour
UST Form 11-MOR (12/01/2021) 12
In re: Clovis Oncology, Inc.
Schedule of Cash
Receipts and Disbursements
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023
Debtor Third-Party Cash Disbursements
Clovis Oncology,
Inc. 1 $76,542,778
Clovis Oncology UK Limited $5,349,082
Clovis Oncology Ireland Limited $134,085
Total $82,025,945
Debtor Third-Party Cash Receipts
Clovis Oncology, Inc.
2 $118,386,058
Clovis Oncology UK Limited $3,402,175
Clovis Oncology Ireland Limited $-
Total $121,788,233
(1) Includes $39.7M in DIP
repayment
(2) Includes $102.3M and $8.5M in proceeds related to the sale of Rubraca and FAP respectively
AlixPartners Genera
In re: Clovis Oncology, Inc.
Bank Account
Information
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023
Debtor Bank Last 4
DigitsDescriptionBalance as of Month End (USD)
Clovis Oncology, Inc. JP Morgan 9101Lockbox Account8,328,224
Clovis Oncology, Inc. JP Morgan 8623Operating Account28,880,863
Clovis
Oncology, Inc. JP Morgan 9601Operating Account80
Clovis Oncology, Inc. JP Morgan 9602Operating Account2,056
Clovis Oncology, Inc. JP Morgan 3424Operating Account446
Clovis Oncology, Inc. JP Morgan 8157Investment Account69,022,573
Clovis Oncology, Inc. JP Morgan 2038Investment Account100,000
Clovis
Oncology, Inc. JP Morgan 1915Professional Fees Account18,056,174
Clovis Oncology, Inc. JP Morgan 7602Utilitiy
Deposits Account10,800
Clovis Oncology, Inc. JP Morgan 7669FAP Proceeds Account1,500,000
Clovis Oncology UK Limited JP Morgan 4225Lockbox Account420,983
Clovis
Oncology UK Limited JP Morgan 2330Operating Account6,211,218
Clovis Oncology Ireland Limited JP Morgan 0565Lockbox
Account2,207,853
Clovis Oncology Ireland Limited JP Morgan 1185Operating Account225,735
Sub TotalBank Accounts 134,967,004
Total 134,967,004
#AlixPartners General
In re: Clovis Oncology, Inc. Unaudited Balance Sheet as of May 31, 2023 Lead Case No:
22-11292 (JKS) Reporting Period: May 01May 31, 2023 USD Actuals Clovis Oncology, Inc. Clovis Oncology UK Limited Clovis Oncology Ireland Limited
Assets Current Assets: Cash and Cash Equivalents 125,901,215 6,632,2012,433,588 Trade Accounts Receivable, Net 1,715,811 1,574,298- Interco
Receivables 23,824,280 35021,431,258 Pre-PetitionInter Company Debtor Receivables Inventories - -- Prepayments and Deposits 14,406,182
126,0303,408 Other AssetsCurrent 226,394 2,316,152880,183 IC Investment in Subsidiaries 2 229,143- Total Current Assets 166,073,884 10,878,17324,748,437 Non-Current Assets: Property, Plant and Equipment, Net 127,026 108,828- Goodwill 63,074,218 -- Other Intangible Assets,
Net - -- Other AssetsNon-current 4,813,211 135,70525,949 Total Non-Current Assets Total
Assets 68,014,455 234,088,339 244,533 11,122,706 25,949 24,774,386 Liabilities Current Liabilities: DIP
Financing 5,276,243 -- Trade Accounts Payable, Net 4,798,437 13,55110,925 Interco Payables 7,914,715 5,833,62518,291,125 Misc. Liabilities & Accrued
Expenses 21,137,559 2,635,098184,128 Accrued Taxes (Income, Payroll, etc.) (16,203) 1,110,406272,309 Lease LiabilityShort-term 49,700 113,93217,497 Other Notes
PayableCurrent - -- Total Current Liabilities 39,160,451 9,706,61318,775,983 Non-Current Liabilities Lease
LiabilityLong-term - -6,748 Total Non-Current Liabilities - -6,748 Liabilities Subject to Compromise 822,895,943 778,50921,778 Total
Liabilities 862,056,394 10,485,12218,804,510
Equity Common Stock 145,470 2141 Additional Paid
in Capital 2,691,516,957 -- Accumulated Other Comprehensive Loss (41,905,090) (461,115)27,615 Accumulated Deficit (3,277,725,392) 1,098,6985,942,121 Total Equity Total Liabilities
and Equity (627,968,055) 234,088,339 637,584 11,122,706 5,969,877 24,774,386 Notes: 1) The financial statements and supplemental information contained herein are limited in scope
and cover a limited time period. Moreover, such information is
preliminary, unaudited, and subject to change. AlixPartners General
In re: Clovis Oncology, Inc.
Unaudited Statement
of Operations for the month of May 2023
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023
USD Actuals Clovis Oncology,
Inc. Clovis Oncology UK
Limited Clovis Oncology Ireland
Limited
Total Revenue (432,544) 44,4018,474,789
Operating Expenses:
Cost of Goods
Sold 7,310 -8,501,577
Royalty Expense (32,660) --
Research and Development (1,238,997) --
General and
Administrative 4,321,718 431,10352,148
Selling Expenses 228,165 13,808-
Operating Taxes 28,649 --
Other Operating
Expenses ---
Total Operating Expenses 3,314,185 444,9118,553,725
Total Operating Profit (Loss) (3,746,729) (400,510)(78,936)
Other
Income and Expenses:
Interest Income 207,080 --
Gain/(Loss) from Asset Sales, Net (51,150,775) --
Interest
Expense - --
Foreign Currency Translation Adjustments 335,223 (132,819)253,761
Gain/(Loss) on Available-For-Sale Securities - --
Reorganization Costs 8,921,368 --
Income Tax
Expense ---
Net Other Income/(Loss) (60,200,286) 132,819(253,761)
Net Income (63,947,015) (267,691)(332,697)
Notes:
1) The financial statements and supplemental
information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results
which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.
AlixPartners General
In re: Clovis Oncology, Inc.
Unaudited Statement
of Operations for the month of May 2023
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023
Clovis Oncology, Inc.
Accounts Receivable Aging 0-30 Days 31-60 Days61-90 Days91+ DaysTotal
Trade Accounts Receivable 1,438,175 --442,9351,881,110
Less: Prompt Pay Discounts & Returns (156,788) --(8,511)(165,299)
Less: Allowance for Bad Debts - ----
Net Accounts
Receivable 1,281,387 --434,4241,715,811
Clovis Oncology UK Limited
Accounts Receivable Aging 0-30 Days 31-60
Days61-90 Days91+ DaysTotal
Trade Accounts Receivable 1,574,298 ---1,574,298
Less: Allowance for Bad Debts - ----
Net Accounts
Receivable 1,574,298 ---1,574,298
Clovis Oncology Ireland Limited
Accounts Receivable Aging 0-30 Days 31-60
Days61-90 Days91+ DaysTotal
Trade Accounts Receivable - ----
Less: Allowance for Bad Debts - ----
Net Accounts
Receivable - ----
#AlixPartners Genera
In re: Clovis Oncology,Inc.
Accounts Receivable
Reconciliation and Aging
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023
Clovis Oncology, Inc.
Debtor Total Current0-30 Days31-60
Days61-90 Days91+ Days
Clovis Oncology, Inc. 4,798,437 243,0182,042,372825,3681,234,824452,855
Clovis Oncology UK Limited 13,551 13,551----
Clovis
Oncology Ireland Limited 10,925 9,378---1,547
Net Accounts Payable 4,822,914 265,9472,042,372825,3681,234,824454,402
Notes:
1) While the Debtors AP Aging Report
shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to
various provisions of the
bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case.
#AlixPartners General
In re: Clovis Oncology, Inc.
Post-Petition
Accounts Payable Aging
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023
Net Book Value
Computer Equipment 115,396 103,138-
Furniture and
Fixtures (0) 4,919-
Lab Equpment 0 --
Leasehold Improvements 0 (0)-
Licensed
Software - --
Manufacturing Equipment 4,685 --
Office Equipment (0) 771-
Trade Booth - --
Net Book Value 120,081 108,828-
Payments to
Insiders 1,130,345 --
#AlixPartners General
In re: Clovis Oncology, Inc.
Schedule of Payments
to Insiders
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023 In re: Clovis Oncology, Inc.
Schedule of Payments
to Insiders
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023 Payments to Insiders 1,130,345
The Debtor, Clovis
Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of May 1 through May 31, 2023. With respect to insiders, all cash payments made were on account of ordinary course
salaries, court approved incentive or retention payments, and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period.
Notes:
1) The insiders included herein are consistent with those as
defined by the Bankruptcy Code and as included in the Debtors Statements of Financial Affairs. The amount listed Includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other
insurance benefits,
and expense reimbursements.
#AlixPartners General
In re: Clovis Oncology, Inc.
Status of
Post-Petition Taxes
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01May 31, 2023
The Debtor, Clovis Oncology, Inc., and its
affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile
other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute.
/s/ Daniel W. Muehl
Signature of Authorized Individual
6/29/2023
Date
Daniel W. Muehl
Printed Name of Authorized Individual
Executive Vice President and Chief Financial Officer
Title of Authorized Individual
Exhibit 99.3
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology UK Limited § Case No. 22-11293 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 12/11/2022 Months Pending: Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtors Full-Time Employees (current): 8 Debtors Full-Time Employees (as of date of order for relief): 49 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement) Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Andrew Mordkoff Andrew S. Mordkoff Signature of Responsible Party Printed Name of Responsible Party 06/29/2023 Date 787 Seventh Avenue, New York, New York 10019-6099 Address STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies. UST Form 11-MOR (12/01/2021) 1
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $6,855,898 b. Total receipts (net of transfers between accounts) $5,125,385 $18,145,711 c. Total disbursements (net of transfers between accounts) $5,349,082 $19,590,816 d. Cash balance end of month (a+b-c) $6,632,201 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation (c+e) $5,349,082 $19,590,816 Part 2: Asset and Liability Status Current Month (Not generally applicable to Individual Debtors. See Instructions.) a. Accounts receivable (total net of allowance) $1,574,298 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory ( Book Market Other (attach explanation)) $0 d Total current assets $10,878,173 e. Total assets $11,122,706 f. Postpetition payables (excluding taxes) $8,596,207 g. Postpetition payables past due (excluding taxes) $0 h. Postpetition taxes payable $1,110,406 i. Postpetition taxes past due $0 j. Total postpetition debt (f+h) $9,706,613 k. Prepetition secured debt $0 l. Prepetition priority debt $0 m. Prepetition unsecured debt $778,509 n. Total liabilities (debt) (j+k+l+m) $10,485,122 o. Ending equity/net worth (e-n) $637,584 Part 3: Assets Sold or Transferred Current Month Cumulative a. Total cash sales price for assets sold/transferred outside the ordinary course of business $0 $0 b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business $0 $0 c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 Part 4: Income Statement (Statement of Operations) Current Month Cumulative (Not generally applicable to Individual Debtors. See Instructions.) a. Gross income/sales (net of returns and allowances) $44,401 b. Cost of goods sold (inclusive of depreciation, if applicable) $0 c. Gross profit (a-b) $44,401 d. Selling expenses $13,808 e. General and administrative expenses $431,103 f. Other expenses $-132,819 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $0 i. Taxes (local, state, and federal) $0 j. Reorganization items $0 k. Profit (loss) $-267,691 $-3,256,673 UST Form 11-MOR (12/01/2021) 2
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 Part 5: Professional Fees and Expenses Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative a. Debtors professional fees & expenses (bankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi UST Form 11-MOR (12/01/2021) 3
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii UST Form 11-MOR (12/01/2021) 4
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii xcix c ci Approved Approved Paid Current Paid Current Month Cumulative Month Cumulative b. Debtors professional fees & expenses (nonbankruptcy) Aggregate Total Itemized Breakdown by Firm Firm Name Role i ii iii iv v vi vii viii ix x xi xii xiii xiv UST Form 11-MOR (12/01/2021) 5
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 xv xvi xvii xviii xix xx xxi xxii xxiii xxiv xxv xxvi xxvii xxviii xxix xxx xxxi xxxii xxxiii xxxiv xxxv xxxvi xxxvii xxxvii xxxix xl xli xlii xliii xliv xlv xlvi xlvii xlviii xlix l li lii liii liv lv lvi UST Form 11-MOR (12/01/2021) 6
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 lvii lviii lix lx lxi lxii lxiii lxiv lxv lxvi lxvii lxviii lxix lxx lxxi lxxii lxxiii lxxiv lxxv lxxvi lxxvii lxxvii lxxix lxxx lxxxi lxxxii lxxxii lxxxiv lxxxv lxxxvi lxxxvi lxxxvi lxxxix xc xci xcii xciii xciv xcv xcvi xcvii xcviii UST Form 11-MOR (12/01/2021) 7
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 xcix c c. All professional fees and expenses (debtor & committees) $0 $0 $0 $0 Part 6: Postpetition Taxes Current Month Cumulative a. Postpetition income taxes accrued (local, state, and federal) $0 $0 b. Postpetition income taxes paid (local, state, and federal) $0 $0 c. Postpetition employer payroll taxes accrued $0 $0 d. Postpetition employer payroll taxes paid $0 $0 e. Postpetition property taxes paid $0 $0 f. Postpetition other taxes accrued (local, state, and federal) $0 $0 g. Postpetition other taxes paid (local, state, and federal) $0 $0 Part 7: Questionnaire During this reporting period: a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes No b. Were any payments made outside the ordinary course of business Yes No without court approval? (if yes, see Instructions) c. Were any payments made to or on behalf of insiders? Yes No d. Are you current on postpetition tax return filings? Yes No e. Are you current on postpetition estimated tax payments? Yes No f. Were all trust fund taxes remitted on a current basis? Yes No g. Was there any postpetition borrowing, other than trade credit? Yes No (if yes, see Instructions) h. Were all payments made to or on behalf of professionals approved by Yes No N/A the court? i. Do you have: Workers compensation insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) General liability insurance? Yes No If yes, are your premiums current? Yes No N/A (if no, see Instructions) j. Has a plan of reorganization been filed with the court? Yes No k. Has a disclosure statement been filed with the court? Yes No l. Are you current with quarterly U.S. Trustee fees as Yes No set forth under 28 U.S.C. § 1930? UST Form 11-MOR (12/01/2021) 8
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 Part 8: Individual Chapter 11 Debtors (Only) a. Gross income (receipts) from salary and wages $0 b. Gross income (receipts) from self-employment $0 c. Gross income from all other sources $0 d. Total income in the reporting period (a+b+c) $0 e. Payroll deductions $0 f. Self-employment related expenses $0 g. Living expenses $0 h. All other expenses $0 i. Total expenses in the reporting period (e+f+g+h) $0 j. Difference between total income and total expenses (d-i) $0 k. List the total amount of all postpetition debts that are past due $0 l. Are you required to pay any Domestic Support Obligations as defined by 11 Yes No U.S.C § 101(14A)? m. If yes, have you made all Domestic Support Obligation payments? Yes No N/A Privacy Act Statement 28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtors progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustees or examiners duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustees systems of records notice, UST-001, Bankruptcy Case Files and Associated Records. See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F). I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate. /s/ Daniel W. Muehl Daniel W. Muehl Signature of Responsible Party Printed Name of Responsible Party Executive Vice President and Chief Financial Officer 06/29/2023 Title Date UST Form 11-MOR (12/01/2021) 9
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 PageOnePartOne PageOnePartTwo PageTwoPartOne PageTwoPartTwo UST Form 11-MOR (12/01/2021) 10
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 Bankruptcy1to50 Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100 UST Form 11-MOR (12/01/2021) 11
Debtors Name Clovis Oncology UK Limited Case No. 22-11293 PageThree PageFour UST Form 11-MOR (12/01/2021) 12
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Cash Receipts and Disbursements Reporting Period: May 01 May 31, 2023 Debtor Third-Party Cash Disbursements Clovis Oncology, Inc. 1 $ 76,542,778 Clovis Oncology UK Limited $ 5,349,082 Clovis Oncology Ireland Limited $ 134,085 Total $ 82,025,945 Debtor Third-Party Cash Receipts Clovis Oncology, Inc. 2 $ 118,386,058 Clovis Oncology UK Limited $ 3,402,175 Clovis Oncology Ireland Limited $ Total $ 121,788,233 (1) Includes $39.7M in DIP repayment (2) Includes $102.3M and $8.5M in proceeds related to the sale of Rubraca and FAP respectively AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Bank Account Information Reporting Period: May 01 May 31, 2023 Debtor Bank Last 4 Digits Description Balance as of Month End (USD) Clovis Oncology, Inc. JP Morgan 9101 Lockbox Account 8,328,224 Clovis Oncology, Inc. JP Morgan 8623 Operating Account 28,880,863 Clovis Oncology, Inc. JP Morgan 9601 Operating Account 80 Clovis Oncology, Inc. JP Morgan 9602 Operating Account 2,056 Clovis Oncology, Inc. JP Morgan 3424 Operating Account 446 Clovis Oncology, Inc. JP Morgan 8157 Investment Account 69,022,573 Clovis Oncology, Inc. JP Morgan 2038 Investment Account 100,000 Clovis Oncology, Inc. JP Morgan 1915 Professional Fees Account 18,056,174 Clovis Oncology, Inc. JP Morgan 7602 Utilitiy Deposits Account 10,800 Clovis Oncology, Inc. JP Morgan 7669 FAP Proceeds Account 1,500,000 Clovis Oncology UK Limited JP Morgan 4225 Lockbox Account 420,983 Clovis Oncology UK Limited JP Morgan 2330 Operating Account 6,211,218 Clovis Oncology Ireland Limited JP Morgan 0565 Lockbox Account 2,207,853 Clovis Oncology Ireland Limited JP Morgan 1185 Operating Account 225,735 Sub Total Bank Accounts 134,967,004 Total 134,967,004 AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Balance Sheet as of May 31, 2023 Reporting Period: May 01 May 31, 2023 Clovis Oncology UK Clovis Oncology Ireland Clovis Oncology, Inc. USD Actuals Limited Limited Assets Current Assets: Cash and Cash Equivalents 125,901,215 6,632,201 2,433,588 Trade Accounts Receivable, Net 1,715,811 1,574,298 Interco Receivables 23,824,280 350 21,431,258 Pre-Petition Inter Company Debtor Receivables Inventories Prepayments and Deposits 14,406,182 126,030 3,408 Other Assets Current 226,394 2,316,152 880,183 IC Investment in Subsidiaries 2 229,143 Total Current Assets 166,073,884 10,878,173 24,748,437 Non-Current Assets: Property, Plant and Equipment, Net 127,026 108,828 Goodwill 63,074,218 Other Intangible Assets, Net Other Assets Non-current 4,813,211 135,705 25,949 Total Non-Current Assets 68,014,455 244,533 25,949 Total Assets 234,088,339 11,122,706 24,774,386 Liabilities Current Liabilities: DIP Financing 5,276,243 Trade Accounts Payable, Net 4,798,437 13,551 10,925 Interco Payables 7,914,715 5,833,625 18,291,125 Misc. Liabilities & Accrued Expenses 21,137,559 2,635,098 184,128 Accrued Taxes (Income, Payroll, etc.) (16,203) 1,110,406 272,309 Lease Liability Short-term 49,700 113,932 17,497 Other Notes Payable Current Total Current Liabilities 39,160,451 9,706,613 18,775,983 Non-Current Liabilities Lease Liability Long-term 6,748 Total Non-Current Liabilities 6,748 Liabilities Subject to Compromise 822,895,943 778,509 21,778 Total Liabilities 862,056,394 10,485,122 18,804,510 Equity Common Stock 145,470 2 141 Additional Paid in Capital 2,691,516,957 Accumulated Other Comprehensive Loss (41,905,090) (461,115) 27,615 Accumulated Deficit (3,277,725,392) 1,098,698 5,942,121 Total Equity (627,968,055) 637,584 5,969,877 Total Liabilities and Equity 234,088,339 11,122,706 24,774,386 Notes: 1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change. AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Unaudited Statement of Operations for the month of May 2023 Reporting Period: May 01 May 31, 2023 Clovis Oncology UK Clovis Oncology Ireland Clovis Oncology, Inc. USD Actuals Limited Limited Total Revenue (432,544) 44,401 8,474,789 Operating Expenses: Cost of Goods Sold 7,310 8,501,577 Royalty Expense (32,660) Research and Development (1,238,997) General and Administrative 4,321,718 431,103 52,148 Selling Expenses 228,165 13,808 Operating Taxes 28,649 Other Operating Expenses Total Operating Expenses 3,314,185 444,911 8,553,725 Total Operating Profit (Loss) (3,746,729) (400,510) (78,936) Other Income and Expenses: Interest Income 207,080 Gain/(Loss) from Asset Sales, Net (51,150,775) Interest Expense Foreign Currency Translation Adjustments 335,223 (132,819) 253,761 Gain/(Loss) on Available-For-Sale Securities Reorganization Costs 8,921,368 Income Tax Expense Net Other Income/(Loss) (60,200,286) 132,819 (253,761) Net Income (63,947,015) (267,691) (332,697) Notes: 1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future. AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Accounts Receivable Reconciliation and Aging Reporting Period: May 01 May 31, 2023 Clovis Oncology, Inc. Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 1,438,175 442,935 1,881,110 Less: Prompt Pay Discounts & Returns (156,788) (8,511) (165,299) Less: Allowance for Bad Debts Net Accounts Receivable 1,281,387 434,424 1,715,811 Clovis Oncology UK Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable 1,574,298 1,574,298 Less: Allowance for Bad Debts Net Accounts Receivable 1,574,298 1,574,298 Clovis Oncology Ireland Limited Accounts Receivable Aging 0-30 Days 31-60 Days 61-90 Days 91+ Days Total Trade Accounts Receivable Less: Allowance for Bad Debts Net Accounts Receivable AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Post-Petition Accounts Payable Aging Reporting Period: May 01 May 31, 2023 Debtor Total Current 0-30 Days 31-60 Days 61-90 Days 91+ Days Clovis Oncology, Inc. 4,798,437 243,018 2,042,372 825,368 1,234,824 452,855 Clovis Oncology UK Limited 13,551 13,551 Clovis Oncology Ireland Limited 10,925 9,378 1,547 Net Accounts Payable 4,822,914 265,947 2,042,372 825,368 1,234,824 454,402 Notes: 1) While the Debtors AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case. AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Capital Assets Reporting Period: May 01 May 31, 2023 Clovis Oncology UK Clovis Oncology Ireland Clovis Oncology, Inc. USD Actuals Limited Limited Net Book Value Computer Equipment 115,396 103,138 Furniture and Fixtures (0) 4,919 Lab Equpment 0 Leasehold Improvements 0 (0) Licensed Software Manufacturing Equipment 4,685 Office Equipment (0) 771 Trade Booth Net Book Value 120,081 108,828 AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Schedule of Payments to Insiders Reporting Period: May 01 May 31, 2023 Clovis Oncology UK Clovis Oncology Ireland Clovis Oncology, Inc. USD Actuals Limited Limited Payments to Insiders 1,130,345 The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of May 1 through May 31, 2023. With respect to insiders, all cash payments made were on account of ordinary course salaries, court approved incentive or retention payments, and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period. /s/ Daniel W. Muehl 6/29/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual Notes: 1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors Statements of Financial Affairs. The amount listed Includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits, and expense reimbursements. AlixPartners General
In re: Clovis Oncology, Inc. Lead Case No: 22-11292 (JKS) Status of Post-Petition Taxes Reporting Period: May 01 May 31, 2023 The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute. /s/ Daniel W. Muehl 6/29/2023 Signature of Authorized Individual Date Daniel W. Muehl Executive Vice President and Chief Financial Officer Printed Name of Authorized Individual Title of Authorized Individual AlixPartners General
Document and Entity Information |
Jun. 30, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Jun. 30, 2023 |
Entity Registrant Name | Clovis Oncology, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-35347 |
Entity Tax Identification Number | 90-0475355 |
Entity Address, Address Line One | 5500 Flatiron Parkway |
Entity Address, Address Line Two | Suite 110 |
Entity Address, City or Town | Boulder |
Entity Address, State or Province | CO |
Entity Address, Postal Zip Code | 80301 |
City Area Code | 303 |
Local Phone Number | 625-5000 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock par Value $0.001 per Share |
Trading Symbol | CLVSQ |
Security Exchange Name | NONE |
Entity Emerging Growth Company | false |
Amendment Flag | false |
Entity Central Index Key | 0001466301 |
1 Year Clovis Oncology (PK) Chart |
1 Month Clovis Oncology (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions